More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
In some cases, certain classes of anti-amyloid beta (Aβ) drugs resulted in individuals’ brain volume decreasing more rapidly while using the drug than they would have if they had not received treatment at all.
The study’s primary endpoint, amputation-free survival after six months, was seen in 66.1% of CLTI patients who underwent transcatheter arterialization.
Weekend warriors who take brisk walks of around four miles just once or twice per week enjoy lower cardiovascular and all-cause mortality than their sedentary peers.
